Glomerulonephritis Kidney Transplant Recipient Cohort (China)

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a multicenter, prospective observational study enrolling about 300 adults with confirmed glomerulonephritis before kidney transplantation. Participants will be followed from screening through kidney transplantation and for 3 years afterward, with visits every 3 months in year 1 and every 6 months in years 2–3 (eight total visits across sites in Beijing, Guangzhou, and Nanning). The study will collect data on GN recurrence, post-transplant outcomes, and treatment of the primary disease to inform future research, drug development, and translational work. No interventions are assigned; the study observes real-world clinical practice across 10 centers in China.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Age ≥ 18 years.
* Diagnosed with primary GN based on clinical guidelines and/or expert consensus
* Successfully matching completed and confirmed to be scheduled for kidney transplantation.

Exclusion Criteria:

* History of organ transplantation or planned multiple organ transplantation.
* Complicated with malignancy.
* Failure to undergo kidney transplantation for any reason.
* Unable to provide written informed consent form (ICF).

Where it's running

• Research Site
  Nanning, Guangxi, China Recruiting
• Research Site
  Beijing, Beijing Municipality, China Not yet recruiting
• Research Site
  Guangzhou, Guangdong, China Not yet recruiting
• Research Site
  Zhengzhou, Henan, China Not yet recruiting
• Research Site
  Wuhan, Hubei, China Not yet recruiting
• Research Site
  Yantai, Shandong, China Not yet recruiting

Study contacts

• Study coordinator: AstraZeneca Clinical Study Information Center
• Email: information.center@astrazeneca.com
• Phone: 1-877-240-9479

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Understanding the disease burden of hypophosphatasia in Chinese patients

  This study tests how hypophosphatasia affects people in China by collecting real-world data on symptoms, quality of life, and costs.

  Recruiting AstraZeneca · Beijing and 21 other locations · NCT07905287

• Real-world use of selumetinib for adult NF1 with inoperable plexiform neurofibromas

  This registry-following study tests how well and safely selumetinib works in adults with NF1 who have symptomatic, inoperable PN.

  Recruiting AstraZeneca · Beijing and 25 other locations · NCT07888517

• Durvalumab with FLOT before and after surgery for resectable gastric/GEJ cancer in Chinese patients

  This trial tests whether adding durvalumab to FLOT chemotherapy before and after surgery helps Chinese patients with resectable gastric or gastroesophageal junction cancer.

  Recruiting at 11 sites Phase 3 AstraZeneca · Beijing and 40 other locations · NCT07877818

• Torvutatug samrotecan plus bevacizumab as first-line maintenance in non-HRD advanced epithelial ovarian cancer

  This trial tests whether adding torvu-samrotecan to bevacizumab after standard chemotherapy helps people with non-HRD advanced epithelial ovarian cancer live longer without the cancer worsening compared with bevacizumab alone.

  Recruiting at 4 sites Phase 3 AstraZeneca · Tamarac, Florida and 219 other locations · NCT07851025

• AZD0543 safety and PK in healthy adults

  This study tests whether AZD0543 is safe and how it behaves in the body compared with a placebo in healthy adults age 18–55.

  Recruiting at 2 sites Phase 1 AstraZeneca · Los Alamitos, California and 1 other locations · NCT07824622

• Torvutatug samrotecan with or without bevacizumab as maintenance in platinum-sensitive relapsed epithelial ovarian, fallopian tube, or primary peritoneal cancer

  This study tests torvutatug samrotecan, with or without bevacizumab, to see if it helps people with platinum-sensitive relapsed ovarian, fallopian tube, or primary peritoneal cancer stay cancer-free longer after their last platinum therapy.

  Recruiting at 3 sites Phase 3 AstraZeneca · Anchorage, Alaska and 123 other locations · NCT07816666

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.